(Q38638523)

5 September 2017

title

Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus (English)

1 reference

5 September 2017

1 reference

1 reference

1 reference

C Triplitt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

E Cersosimo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

M Abdul-Ghani

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

19 November 2015

1 reference

Expert Opinion on Pharmacotherapy

5 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

2819-2833

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Achievement of goals in U.S. diabetes care, 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Public health implications of recommendations to individualize glycemic targets in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

AACE/ACE comprehensive diabetes management algorithm 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Direct effect of GLP-1 infusion on endogenous glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Improved glycemic control in mice lacking Sglt1 and Sglt2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Studies of pancreatic alpha cell function in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Gut peptides and type 2 diabetes mellitus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Glucagon physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Assessment of pancreatic β-cell function: review of methods and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1114098

10.1517/14656566.2015.1114098

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26583910%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference